Alamar Biosciences, in partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures, initiated a large-scale proteomic profiling project using ultra-sensitive NULISA™ technology across multiple international research centers. The goal is to establish an extensive, clinically annotated plasma proteome dataset for Alzheimer’s and related dementias to accelerate biomarker discovery and therapeutic development. This initiative integrates proteomic data with longitudinal clinical outcomes and promotes global data sharing to enhance neurodegenerative disease research.